ACADIA Pharmaceuticals Balance Sheet
NASDAQ: ACADHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
ACADIA Pharmaceuticals financial position
At the end of fiscal 2025, ACADIA Pharmaceuticals reported total assets of $1.56 billion, up 31.7% from a year earlier against total liabilities of $336.8 million. Shareholders' equity stood at $1.23 billion, or 78.5% of assets. The company held $177.7 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 3.83, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
ACADIA Pharmaceuticals balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 177.69M | 319.59M | 188.66M | 114.85M | 147.44M | 326.03M | 189.68M | 134.76M | 69.42M | 163.62M |
| Short-Term Investments | 641.99M | 436.40M | 250.21M | 301.98M | 373.27M | 305.93M | 507.75M | 338.76M | 271.92M | 365.42M |
| Receivables | 121.46M | 98.74M | 98.27M | 62.20M | 64.37M | 48.25M | 35.78M | 26.09M | 17.34M | 5.90M |
| Inventory | 111.37M | 91.69M | 40.45M | 11.56M | 14.10M | 9.68M | 6.34M | 4.07M | 5.25M | 4.17M |
| Total Current Assets | 1.06B | 938.32M | 616.13M | 507.94M | 617.82M | 717.62M | 760.25M | 526.11M | 373.48M | 547.90M |
| Property, Plant & Equipment | 7.51M | 4.21M | 4.61M | 6.02M | 8.05M | 9.16M | 3.18M | 3.31M | 2.66M | 3.08M |
| Intangible Assets | 108.89M | 119.78M | 65.49M | 0 | 0 | 1.11M | 2.58M | 4.06M | 5.54M | 7.01M |
| Total Assets | 1.56B | 1.19B | 748.96M | 587.81M | 700.12M | 782.62M | 783.18M | 540.20M | 384.51M | 561.15M |
| Accounts Payable | 10.90M | 16.19M | 17.54M | 12.75M | 6.88M | 8.49M | 7.22M | 3.17M | 8.79M | 3.91M |
| Total Current Liabilities | 277.11M | 394.87M | 254.25M | 125.63M | 96.07M | 105.97M | 74.83M | 59.56M | 49.03M | 42.59M |
| Total Liabilities | 336.81M | 454.96M | 317.20M | 187.40M | 159.23M | 155.61M | 84.05M | 61.12M | 49.22M | 42.74M |
| Shareholders' Equity | 1.23B | 732.79M | 431.75M | 400.41M | 540.89M | 627.01M | 699.13M | 479.08M | 335.29M | 518.41M |
| Retained Earnings | -1.81B | -2.20B | -2.43B | -2.37B | -2.15B | -1.99B | -1.70B | -1.47B | -1.22B | -933.98M |
| Net Cash (Debt) | 819.69M | 755.99M | 438.87M | 416.82M | 520.71M | 631.96M | 697.43M | 473.52M | 341.34M | 529.04M |
| Shares Outstanding | 170.31M | 166.71M | 164.65M | 162.06M | 161.01M | 159.64M | 155.28M | 143.85M | 124.41M | 121.37M |
This table shows 10 annual periods of ACADIA Pharmaceuticals's balance sheet, from FY 2025 back to FY 2016, across 17 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow ACAD's reporting calendar. What is a balance sheet?